Evidence map›Paper›PMID 32779952›Full record

Trial reportOcular immunology and inflammation2022

Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.

Christina L Kong, Nicole K Kelly, Miel Sundararajan, S R Rathinam, John A Gonzales, Radhika Thundikandy, Rajesh Vedhanayaki, Anuradha Kanakath, Bala Murugan, Thuy Doan and 3 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ocular immunology and inflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01829295 (First-line Antimetabolites as Steroid-sparing Treatment), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01829295 phase3completednot on this map

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2018Enrolled216ConditionsUveitisArmsMycophenolate mofetil, Methotrexate, Prednisone
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. DisseminatedACG case reports journal · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Christina L KongF.I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA.
Nicole K KellyF.I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA.
Miel SundararajanDepartment of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
S R RathinamUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
John A GonzalesF.I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0558-9793
Radhika ThundikandyUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Rajesh VedhanayakiUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Anuradha KanakathUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Coimbatore, India.
Bala MuruganUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Pondicherry, India.
Thuy DoanF.I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-2733-8370
Debra GoldsteinDepartment of Ophthalmology, Northwestern University, Chicago, IL, USA.
Hassan A Al-DhibiDivision of Vitreoretinal Surgery and Uveitis, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia.
Nisha R AcharyaF.I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9762-9475
University of California, San Francisco · USAravind Eye Hospital · INKing Khaled Eye Specialist Hospital · SANorthwestern University · US

Funding

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis TrialU10EY021125 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ACHARYA, NISHA · 2012 to 2016
$4.6M
NEI NIH HHS U10 EY021125
6 · The paper itself

Abstract

purposeSub-analysis of the FAST Trial comparing change in CD4 (∆CD4) from baseline through 12 months in uveitis patients treated with mycophenolate mofetil (MMF) and methotrexate (MTX).

methodsPatients were randomly allocated to 1.5 g twice daily MMF or 25 mg weekly MTX. Individuals with CD4 counts at baseline, 6 months (or treatment failure prior), and 12 months (or treatment failure between 6 and 12 months) were included. The association between treatment and ∆CD4 (cells/μL) was analyzed using multivariable linear regression.

resultsThere was no significant difference in ∆CD4 between MMF and MTX at 6 months (-31.7 cells/μL for MMF compared to MTX; 95% CI: -358.2 to 294.8,

conclusionThere was no significant difference in ∆CD4 between MMF and MTX from baseline to 12 months, suggesting that MMF does not confer additional risk of CD4 lymphopenia in uveitic patients.ClinicalTrials.gov Identifier: NCT01829295.

Indexed as

Mycophenolic AcidUveitisAntimetabolitesCD4 Lymphocyte CountHumansImmunosuppressive AgentsMethotrexateSteroidsAntimetabolitesImmunosuppressive AgentsMethotrexateMycophenolic AcidSteroidsantimetaboliteCD4methotrexatemycophenolate mofetiluveitis

Identifiers

PMID32779952
PMCPMC7876156
OpenAlexW3048908572

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.